Off the wire
1st LD: Rebels start evacuating eastern part of Aleppo city  • Greek debt relief will not lead to fourth bailout: Greek FinMin  • Iran says only Iraqis should partake in Mosul operation  • Oil prices jump on big U.S. crude stock drawdown  • Iranian warships enter Baku port on friendly visit  • Drought blamed for rise of human-wildlife conflict in Kenya  • Ethiopia joins African Trade Insurance Agency  • Bulgarian president urges EU to back trade deal with Canada  • Egypt, FAO officials tour rural development project amid WFD celebrations  • French poll shows more approval of ex-economy minister as election approaches  
You are here:   Home

Roundup: Price of children's five-in-one vaccine halved to below 1 U.S. dollar a dose, UNICEF says

Xinhua, October 20, 2016 Adjust font size:

The UN Children's Fund (UNICEF) said on Wednesday that the price of a vaccine that protects children against five deadly diseases has been halved to below 1 U.S. dollar a dose.

"Over the next three years, UNICEF will buy 450 million doses of this vaccine to send to 80 countries," UN spokesman Stephane Dujarric said at a daily news briefing here.

"The vaccine will protect tens of millions of children from diseases including diphtheria, tetanus, pertussis, and hepatitis B," he said.

Shanelle Hall, UNICEF's director of supply and procurement, said that "for the most vulnerable children in the world, pricing can make a difference between life and death."

Breakthrough prices have been achieved with six vaccine suppliers who offered to price pentavalent vaccine at 84 cents a dose average -- half the price that the UN children's agency currently pays.

Since 2001, strong collaboration on market shaping across Gavi Alliance partners, including the Bill & Melinda Gates Foundation, the World Health Organization (WHO) and UNICEF, has achieved an affordable and sustainable pentavalent vaccine supply for children in the world's poorest countries.

The new pricing can also be accessed by governments who self-finance procurement of this cost-effective vaccine. It will generate over 366 million U.S. dollars in savings for donors and for governments.

"Ninety percent of the world's children under five who die from vaccine-preventable diseases live in countries whose vaccine supply is no longer fully funded by donors," Hall said.

"Gavi estimates that 5.7 million deaths will be averted thanks to pentavalent vaccination in Gavi-supported countries between 2011 and 2020," said Seth Berkley, CEO of Gavi, the Vaccine Alliance. "The market for five-in-one vaccines is now a lot healthier than it was just a few years ago thanks to our collective efforts to grow a base of vaccine suppliers."

"We remain committed to making vaccine markets work better for the world's poorest countries to ensure immunization investments and efforts are sustainable for all," Berkley said.

Achieving milestones in making vaccines more affordable illustrates how collaborative engagement, including with vaccine suppliers, can result in vaccine markets that put children's health first.

Careful monitoring of supply and demand in vaccine markets and consultations with vaccine manufacturers have helped determine the most effective actions to secure sufficient production levels and efficiencies of scale.

Between 2001 and 2015, UNICEF's pentavalent vaccine procurement jumped from 14.5 million to more than 235 million doses, mainly driven by the increase in demand in countries supported by Gavi.

Broadening the supplier base reduces the risk of supply shortages and other serious market constraints that could negatively impact children.

Collaboration between Gavi, the Gates Foundation and UNICEF leveraged the significant donor funding and through multi-year supplier contracts, improved demand forecasts and special contracting terms, helped grow the pentavalent vaccine supplier base from one in 2001 to six by 2016, and reduce prices.

As additional manufacturers become interested in supplying vaccines to UNICEF, competition between them intensifies.

Since 2011, UNICEF publishes the prices of all vaccines it procures, giving manufacturers the advantage of seeing what their competitors charge -- and this had led to better offers. By 2016, the price for donor-funded and government self-funded pentavalent vaccines was an average of 1.65 U.S. dollars a dose.

In 2016, a competitive pentavalent vaccine market and excess supply capacity represented ideal conditions to launch a new phased approach to tendering.

In the first phase, UNICEF invited interested suppliers to submit a proposed price. After making awards to the most competitive bids, UNICEF published prices and launched a second request for proposals, which gave time for suppliers to sharpen their initial offers. The final awards achieved lowest ever pricing while sustaining a healthy supply market for the longer-term.

"Today's announcement demonstrates that partnerships can bring affordability and price sustainability to the table in supplier discussions, and this is transforming health outcomes for children," said Hall. Endit